date:Nov 02, 2012
s awarded Generally Regarded As Safe (GRAS) status for its acrylamide-preventing yeast strains.
The firm's chief technology and innovation officer, Dr John Husnik, said he expected the GRAS-status product to be available for full commercial use in the near future.
We have not released the product for full commercial scale sales at this point; all sales are related to bench and pilot scale runs. Once we have our commercial production capacity in place we expect to move to full commercial scale